China Lobaplatin Research Markets Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 – ResearchAndMarkets.com


DUBLIN–()–The “Research Report on China’s Lobaplatin Market, 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

According to the publisher’s market research, there are five types of platinum-based antitumor drugs commonly used in China: first-generation cisplatin, second-generation carboplatin and nedaplatin, third-generation oxaliplatin and lobaplatin. Lobaplatin, 1,2-diammino-methy lcyclobutane-platinum (II) lactate, was developed in Germany.

In 2002, China’s Hainan Changan International Pharmaceutical purchased the patent right and the production and selling rights in China from ASAT, a German company. In 2005, its lobaplatin production was approved by the NMPA of China and marketed as a new Category I drug.

In addition to affecting DNA synthesis and replication, its mechanism also affects the expression of the original tumor gene c-mye which is involved in oncogenesis, apoptosis and cell proliferation. The approved indications for lobaplatin in China are advanced breast cancer, small cell lung cancer and chronic myelomonocytic leukemia (CMML).

According to the publisher’s market research, since its launch in China, lobaplatin showed an upward trend in sales volume and value from 2005 to 2019. In 2020, the sales value of lobaplatin in China declined to USD472 million due to the outbreak of COVID-19 at the beginning of the year which affected the proper functioning of Chinese healthcare institutions, but the CAGR from 2016 to 2020 was still up to 20.3%.

The publisher expects that sales of lobaplatin in China will recover gradually from 2021 to 2025 as the COVID-19 is effectively controlled in the country. And the rising incidence of advanced breast cancer, small cell lung cancer and chronic granulocytic leukemia in China caused by increasing environmental pollution and changing lifestyles will boost the sales of lobaplatin.

Generic drugs of lobaplatin are also expected to be available in China in the next few years, which will lower the average sales price of lobaplatin and increase the sales volume.

Topics Covered:

  • The Impact of COVID-19 on China’s Lobaplatin Market
  • The Incidence of Cancer in China
  • The Development Environment of Lobaplatin in China
  • Sales Volume of Lobaplatin in China
  • Sales Volume and Value of Lobaplatin in China by Region
  • Major Lobaplatin Manufacturers in China and Their Market Shares
  • Price of Lobaplatin in China’s market
  • Prospects of China’s Lobaplatin Market, 2021-2025

Key Topics Covered:

1 Relevant Concept of Lobaplatin

1.1 Indications for Lobaplatin

1.2 Development of China’s Lobaplatin Market

1.3 Governmental Approval of Lobaplatin in China

1.4 The Impact of COVID-19 on China’s Lobaplatin Market

2 Sales of Lobaplatin in China, 2016-2020

2.1 Sales Value

2.1.1 Sales Value in China

2.1.2 Sales Value in China by Region

2.2 Sales Volume

2.2.1 Sales Volume in China

2.2.2 Sales Volume in China by Region

2.3 Sales of Lobaplatin in China by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Other Dosage Forms

3 Analysis of Major Lobaplatin Manufacturers in China, 2020

3.1 Analysis of Market Share

3.1.1 Market Share of Manufacturers by Sales Value

3.1.2 Market Share of Manufacturers by Sales Volume

3.2 Hainan Changan International Pharmaceutical Co. Ltd

3.2.1 Company Profile

3.2.2 Sales of Lobaplatin in China

4 Sales Price of Lobaplatin of Different Companies in China, 2020-2021

4.1 Hainan Changan International Pharmaceutical Co.

5 Prospects of China’s Lobaplatin Market, 2021-2025

5.1 Influencing Factors for the Market Development

5.1.1 The Impact of COVID-19 on the Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/b7cb9n



Source link

The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

Comments are closed.